Nasdaq · Biotech stocks database
TENX (Tenax Therapeutics Inc.) stock: $1.69, $63.2M market cap, $113.7M cash, -$50.5M EV, $89.3M fully diluted market cap. Lead program: TNX-103 (Pulmonary Hypertension), Phase 3. Data from Fully Diluted's biotech stocks database.
We employ a clinician-driven drug development approach, led by key opinion leaders and heart failure experts and informed by their clinical insights to precisely target disease pathophysiology. We are currently actively conducting the LEVEL and LEVEL-2 clinical trials to evaluate levosimendan as our prioritized product candidate and have deprioritized a Phase 3 clinical trial of imatinib, two drugs supported by promising evidence that they may significantly improve the lives of patients with pulmonary hypertension.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $113.7M |
|---|---|
| Debt | $0.0M |
| Net cash | $113.7M |
| Enterprise value | -$50.5M |
| Basic shares | 45.5M shares |
| Fully diluted shares | 52.8M shares |
| Fully diluted market cap | $89.3M |
| Cash per share | $2.50 |
| Quarterly burn | $14.2M |
| Cash runway | 8.3 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Loading TENX daily closes…
TNX-103 · Aug 11 - Sep 22 in 21 mo · Phase 3 · Pulmonary Hypertension Associated With HFpEF